Prediction of the response to chemotherapy in acute leukemia.

Sensitivity of normal and acute myelogenous leukaemia marrow cells to inhibition by cytosine arabinoside. Br J Cancer (1980) 0.78

Lack of prognostic value of the thymidine-labelling index in adult acute leukaemia. Br J Cancer (1981) 0.78

Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications. J Clin Invest (1985) 0.75

Symptoms of anxiety and depression in family members of intensive care unit patients: ethical hypothesis regarding decision-making capacity. Crit Care Med (2001) 3.98

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol (1989) 2.43

French intensivists do not apply American recommendations regarding decisions to forgo life-sustaining therapy. Crit Care Med (2001) 2.39

Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res (1996) 1.95

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet (1992) 1.92

Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood (1998) 1.90

Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry. Biophys J (2000) 1.58

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood (2001) 1.48

Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression. Br J Haematol (1998) 1.44

Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Cancer Clin Oncol (1989) 1.40

In vitro sensitivity of normal and leukemic myeloid clonogenic cells to hyperthermia: absence of selective effect. Exp Hematol (1989) 1.38

GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene (2009) 1.37

Plumbing in the embryo: developmental defects of the urinary tracts. Clin Genet (2009) 1.33

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol (1998) 1.32

Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood (1991) 1.29

Comparative efficacies of erythromycin-sulfisoxazole and cefaclor in acute otitis media: a double blind randomized trial. Pediatr Infect Dis J (1987) 1.29

A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia (1997) 1.28

Compliance with triage to intensive care recommendations. Crit Care Med (2001) 1.28

Overexpression of cyclin D2 in chronic B-cell malignancies. Blood (1995) 1.26

Amyloid fibril formation by a helical cytochrome. FEBS Lett (2001) 1.21

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia (2003) 1.21

Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood (1998) 1.21

Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med (1998) 1.17

Partial deletion of a group-F (19-20) chromosome in a physically handicapped psychiatric male patient. J Med Genet (1971) 1.16

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood (2000) 1.12

Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia (1997) 1.10

Indoor exposure to polycyclic aromatic hydrocarbons and carbon monoxide in traditional houses in Burundi. Int Arch Occup Environ Health (2000) 1.08

Acute renal failure following collective intoxication by Cortinarius orellanus. Intensive Care Med (1990) 1.07

Distinct regulators control the expression of the mid-hindbrain organizer signal FGF8. Nat Neurosci (2001) 1.06

Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer (1999) 1.06

[Chromosome analyses in idiopathic acquired sideroblastic anemia. A study of 6 cases]. Nouv Rev Fr Hematol (1967) 1.06

Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood (1998) 1.04

Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood (2001) 1.02

Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood (1999) 1.01

Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood (1997) 0.99

Pax2 and homeodomain proteins cooperatively regulate a 435 bp enhancer of the mouse Pax5 gene at the midbrain-hindbrain boundary. Development (2000) 0.98

A toxicokinetic model for predicting the tissue distribution and elimination of organic and inorganic mercury following exposure to methyl mercury in animals and humans. II. Application and validation of the model in humans. Toxicol Appl Pharmacol (2001) 0.97

Models for clonal evolutions: a study of chronic myelogenous leukemia. Am J Hum Genet (1966) 0.96

The characterization of novel Pax genes of the sea urchin and Drosophila reveal an ancient evolutionary origin of the Pax2/5/8 subfamily. Mech Dev (1997) 0.96

Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia (1993) 0.96

Epidemic Pseudomonas aeruginosa serotype O16 bacteremia in hematology-oncology patients. J Clin Microbiol (1989) 0.95

Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant (2000) 0.94

A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol (1996) 0.94

Fournier's gangrene during induction treatment of acute promyelocytic leukemia, a case report. Ann Hematol (1998) 0.94

Annotation: Subacute and chronic myelomonocytic leukaemia: a distinct haematological entity. Br J Haematol (1976) 0.94

The persistent Müllerian duct syndrome: a molecular approach. J Clin Endocrinol Metab (1989) 0.93

Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol (1999) 0.93

Serum antibodies to Bacteroides gingivalis in periodontitis: a longitudinal study. J Periodontal Res (1987) 0.92

MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer (1996) 0.91

Modern clinical testing strategies in cobalamin and folate deficiency. Semin Hematol (1999) 0.90

The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia (2003) 0.89

Waldenström's macroglobulinaemia in a bird breeder: a case history with pulmonary involvement and antibody activity of the monoclonal IgM to canary's droppings. Clin Exp Immunol (1987) 0.89

Letter: HL-A and pernicious anemia. N Engl J Med (1975) 0.89

[Waldenstrôm's macroglobulinemia. Developmental and prognostic study]. Sem Hop (1975) 0.88

Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer (1995) 0.88

Spontaneous remission in adult acute leukemia. Cancer (1985) 0.88

Effect of folate and cobalamin compounds on the deoxyuridine suppression test in vitamin B12 and folate deficiency. Blood (1978) 0.88

Sleep EEG studies in untreated, long-term schizophrenic patients. Arch Gen Psychiatry (1973) 0.88

N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant (1993) 0.87

Disseminated superficial porokeratosis after autologous bone marrow transplantation. Bone Marrow Transplant (1997) 0.87

Prognostic value of clonogenic assay for induction and duration of complete remission in acute myelogenous leukemia. Leukemia (1987) 0.86

[Subacute myelo-monocytic leukemia. Study of 27 cases and review of the literature]. Sem Hop (1972) 0.85

Splenic marginal zone lymphoma with or without plasmacytic differentiation. Am J Surg Pathol (2000) 0.85

Normal human bone marrow cultures in vitro: cellular composition and maturation of the granulocytic colonies. Br J Haematol (1977) 0.85

Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia. Br J Haematol (1992) 0.85

A toxicokinetic model for predicting the tissue distribution and elimination of organic and inorganic mercury following exposure to methyl mercury in animals and humans. I. Development and validation of the model using experimental data in rats. Toxicol Appl Pharmacol (2001) 0.85

[Pseudolymphoma and lymphoproliferative syndromes in Gougerot-Sjögren syndrome (author's transl)]. Sem Hop (1979) 0.85

[In vitro effect of antibiotics against hospital strains of Acinetobacter baumanii]. Pathol Biol (Paris) (1989) 0.85

A modular questionnaire for the assessment of longterm quality of life in leukaemia patients: the MRC/EORTC QLQ-LEU. Qual Life Res (1996) 0.85

Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. Br J Haematol (1996) 0.85

Sphenoid sinus localization of multiple myeloma revealing evolution from benign gammopathy. Head Neck (1997) 0.84

Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol (1994) 0.84

[Transmission of a small Y through 11 generations in a familial line]. Ann Genet (1970) 0.84

European undergraduate education in oncology. A report of the EORTC Education Branch. Acta Oncol (1988) 0.84

The three transcobalamins in myeloproliferative disorders and acute leukaemia. Br J Haematol (1975) 0.84

Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia (1992) 0.84

[Polycythemia resulting from abnormal hemoglobin with increased affinity for oxygen. Two cases (author's transl)]. Nouv Presse Med (1980) 0.84

Acute leukaemia in workers exposed to electromagnetic fields. Eur J Cancer (1990) 0.83

Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood (1986) 0.83

[Congenital and familial dysfibrinogenemia without hemorrhagic tendancy]. Nouv Rev Fr Hematol (1970) 0.83

Poliovirus attenuation and pathogenesis in a transgenic mouse model for poliomyelitis. Dev Biol Stand (1993) 0.83

Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia (1995) 0.83

Cobalamin (vitamin B12) and B12 binding proteins in hypereosinophilic syndromes and secondary eosinophilia. Blood (1984) 0.83

[Waldenström's macroglobulinemia with preserved antierythrocyte and antilipoprotein antibody activity]. Sem Hop (1975) 0.82

Occupational risk factors for acute leukaemia: a case-control study. Int J Epidemiol (1992) 0.82

[Pregnancy and hematologic malignancies: a therapeutic approach]. Bull Cancer (1994) 0.82

Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia (1995) 0.82

Acquired von Willebrand disease: correction of hemostatic defect by high-dose intravenous immunoglobulins. Am J Hematol (1992) 0.82

[Polyglobulia and hemangioma of the cerebellum. Report of 2 cases with demonstration of an erythropoietic substance in the tumor and plasma]. Presse Med (1965) 0.82

Fatigue in cancer patients. Curr Opin Oncol (1999) 0.82

Autologous bone marrow transplantation with marrow decontaminated by immunotoxin T 101 in the treatment of leukemia and lymphoma: first clinical observations. Cancer Treat Rep (1985) 0.81

Relative value of allogeneic BMT, autologous BMT and intensive chemotherapy during the first complete remission (CR) of acute myelogenous leukemia (AML). An interim analysis of the AML8 EORTC-GIMEMA protocol. Bone Marrow Transplant (1990) 0.81

Over-expression of cyclin D1 in chronic B-cell malignancies with abnormality of chromosome 11q13. Br J Haematol (1995) 0.81

The toxicokinetics of pyrene and its metabolites in rats. Toxicol Lett (1999) 0.81

Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules. Blood (1997) 0.81

Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia (1998) 0.81